News and Updates

Breakthrough T1D headed to Washington D.C. where advocates held nearly 500 meetings with Members of Congress on behalf of the T1D community.

While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures and improving everyday life with T1D.   This wouldn’t have been possible without each and every one of you and your continued support of our mission as we drive toward cures for T1D.   Here are the […]

On October 1st, the T1D community got a big win: the Centers for Medicare and Medicaid Servies (CMS) introduced a unique ICD-10 code for stage 2 type 1 diabetes (T1D). This addresses a significant gap in clinical care. Prior to this change, clinicians had limited options for coding stage 2 T1D, which resulted in inaccurate […]

With the support of our grassroots advocates, our work helps advance treatments, influence policy, and improve access to care for those worldwide who need it.

Our Advocates traveled to D.C. to reintroduce our organization and champion legislation and policy for the T1D community.

The true story of how Tzield (teplizumab), the first disease-modifying therapy approved for use in delaying type 1 diabetes (T1D) onset, made it to market.

In 2023 alone, there have been several important papers published on disease-modifying therapies (DMT) for type 1 diabetes. This blog explains everything you need to know about several DMTs.

Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.

JDRF’s Chief Mission Strategy Officer will leave behind quite a legacy once she steps down from her role at Breakthrough T1D at the end of March 2023.

There is tremendous progress in accelerating cures, improving lives, and advocating for people with T1D and their loved ones over the past year.